$113 Million is the total value of Casdin Capital, LLC's 31 reported holdings in Q4 2015. The portfolio turnover from Q3 2015 to Q4 2015 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BPMC | New | BLUEPRINT MEDICINES CORP | $10,865,000 | – | 412,500 | +100.0% | 9.60% | – |
| SAGE | New | SAGE THERAPEUTICS INC | $8,338,000 | – | 143,011 | +100.0% | 7.37% | – |
| LOXO | New | LOXO ONCOLOGY INC | $7,155,000 | – | 251,500 | +100.0% | 6.32% | – |
| CTMX | New | CYTOMX THERAPEUTICS INC | $6,700,000 | – | 321,023 | +100.0% | 5.92% | – |
| ONCE | New | SPARK THERAPEUTICS INC | $6,570,000 | – | 145,000 | +100.0% | 5.80% | – |
| BLUE | New | BLUEBIRD BIO INC | $6,422,000 | – | 100,000 | +100.0% | 5.67% | – |
| AGIO | New | AGIOS PHARMACEUTICALS INC | $6,265,000 | – | 96,500 | +100.0% | 5.54% | – |
| MYOK | New | MYOKARDIA INC | $5,921,000 | – | 403,872 | +100.0% | 5.23% | – |
| GHDX | New | GENOMIC HEALTH INC | $5,808,000 | – | 165,000 | +100.0% | 5.13% | – |
| ILMN | New | ILLUMINA INC | $5,758,000 | – | 30,000 | +100.0% | 5.09% | – |
| ALNY | New | ALNYLAM PHARMACEUTICALS INC | $5,648,000 | – | 60,000 | +100.0% | 4.99% | – |
| EPZM | New | EPIZYME INC | $5,327,000 | – | 332,500 | +100.0% | 4.71% | – |
| VYGR | New | VOYAGER THERAPEUTICS INC | $5,187,000 | – | 236,862 | +100.0% | 4.58% | – |
| ILMN | New | ILLUMINA INCcall | $3,839,000 | – | 20,000 | +100.0% | 3.39% | – |
| BIIB | New | BIOGEN INC | $2,757,000 | – | 9,000 | +100.0% | 2.44% | – |
| FMI | New | FOUNDATION MEDICINE INC | $2,422,000 | – | 115,000 | +100.0% | 2.14% | – |
| GNMK | New | GENMARK DIAGNOSTICS INC | $2,406,000 | – | 310,000 | +100.0% | 2.13% | – |
| BMY | New | BRISTOL MYERS SQUIBB CO | $2,213,000 | – | 32,164 | +100.0% | 1.96% | – |
| GBT | New | GLOBAL BLOOD THERAPEUTICS IN | $2,101,000 | – | 65,000 | +100.0% | 1.86% | – |
| NVTA | New | INVITAE CORP | $2,053,000 | – | 250,000 | +100.0% | 1.81% | – |
| KITE | New | KITE PHARMA INC | $1,849,000 | – | 30,000 | +100.0% | 1.63% | – |
| DXCM | New | DEXCOM INC | $1,392,000 | – | 17,000 | +100.0% | 1.23% | – |
| BLUE | New | BLUEBIRD BIO INCcall | $1,284,000 | – | 20,000 | +100.0% | 1.13% | – |
| OSUR | New | ORASURE TECHNOLOGIES INC | $1,095,000 | – | 170,000 | +100.0% | 0.97% | – |
| OXFD | New | OXFORD IMMUNOTEC GLOBAL PLC | $863,000 | – | 75,000 | +100.0% | 0.76% | – |
| JUNO | New | JUNO THERAPEUTICS INC | $769,000 | – | 17,500 | +100.0% | 0.68% | – |
| ATRA | New | ATARA BIOTHERAPEUTICS INC | $660,000 | – | 25,000 | +100.0% | 0.58% | – |
| MDSO | New | MEDIDATA SOLUTIONS INC | $493,000 | – | 10,000 | +100.0% | 0.44% | – |
| TROV | New | TROVAGENE INC | $378,000 | – | 70,000 | +100.0% | 0.33% | – |
| AGIO | New | AGIOS PHARMACEUTICALS INCcall | $325,000 | – | 5,000 | +100.0% | 0.29% | – |
| FMI | New | FOUNDATION MEDICINE INCcall | $316,000 | – | 15,000 | +100.0% | 0.28% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-02-08
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BLUEPRINT MEDICINES CORP | 32 | Q3 2023 | 9.6% |
| ALNYLAM PHARMACEUTICALS INC | 32 | Q3 2023 | 9.9% |
| AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
| GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
| FATE THERAPEUTICS INC | 26 | Q3 2023 | 8.3% |
| BIOLIFE SOLUTIONS INC | 22 | Q3 2023 | 14.9% |
| CODEXIS INC | 22 | Q3 2023 | 8.1% |
| SAREPTA THERAPEUTICS INC | 21 | Q3 2023 | 13.6% |
| BLUEBIRD BIO INC | 21 | Q4 2020 | 7.8% |
| ILLUMINA INC | 21 | Q3 2023 | 6.0% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
| CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Tango Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Verve Therapeutics, Inc. | February 14, 2023 | 2,290,571 | 3.7% |
| Tenaya Therapeutics, Inc. | December 07, 2022 | 6,427,200 | 9.9% |
| Fulcrum Therapeutics, Inc. | February 11, 2021 | 1,241,176 | 4.5% |
| Gritstone Oncology, Inc.Sold out | February 11, 2021 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-02 |
| SC 13G | 2024-04-18 |
| SC 13D/A | 2024-04-08 |
| 4 | 2024-03-28 |
| 3 | 2024-03-25 |
| 4 | 2024-03-25 |
| 4 | 2024-03-20 |
| SC 13D/A | 2024-03-20 |
| 4 | 2024-03-06 |
| 4 | 2024-03-06 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.